112 related articles for article (PubMed ID: 35524694)
1. Association of osteopontin with kidney function and kidney failure in chronic kidney disease patients: the GCKD study.
Steinbrenner I; Sekula P; Kotsis F; von Cube M; Cheng Y; Nadal J; Schmid M; Schneider MP; Krane V; Nauck M; Eckardt KU; Schultheiss UT;
Nephrol Dial Transplant; 2023 May; 38(6):1430-1438. PubMed ID: 35524694
[TBL] [Abstract][Full Text] [Related]
2. Genetics of osteopontin in patients with chronic kidney disease: The German Chronic Kidney Disease study.
Cheng Y; Li Y; Scherer N; Grundner-Culemann F; Lehtimäki T; Mishra BH; Raitakari OT; Nauck M; Eckardt KU; Sekula P; Schultheiss UT;
PLoS Genet; 2022 Apr; 18(4):e1010139. PubMed ID: 35385482
[TBL] [Abstract][Full Text] [Related]
3. Kidney Function as Risk Factor and Predictor of Cardiovascular Outcomes and Mortality Among Older Adults.
Kühn A; van der Giet M; Kuhlmann MK; Martus P; Mielke N; Ebert N; Schaeffner ES
Am J Kidney Dis; 2021 Mar; 77(3):386-396.e1. PubMed ID: 33197533
[TBL] [Abstract][Full Text] [Related]
4. Circulating levels of osteopontin are closely related to glomerular filtration rate and cardiovascular risk markers in patients with chronic kidney disease.
Lorenzen J; Krämer R; Kliem V; Bode-Boeger SM; Veldink H; Haller H; Fliser D; Kielstein JT
Eur J Clin Invest; 2010 Apr; 40(4):294-300. PubMed ID: 20486990
[TBL] [Abstract][Full Text] [Related]
5. Nonalbuminuric Diabetic Kidney Disease and Risk of All-Cause Mortality and Cardiovascular and Kidney Outcomes in Type 2 Diabetes: Findings From the Hong Kong Diabetes Biobank.
Jin Q; Luk AO; Lau ESH; Tam CHT; Ozaki R; Lim CKP; Wu H; Jiang G; Chow EYK; Ng JK; Kong APS; Fan B; Lee KF; Siu SC; Hui G; Tsang CC; Lau KP; Leung JY; Tsang MW; Kam G; Lau IT; Li JK; Yeung VT; Lau E; Lo S; Fung S; Cheng YL; Chow CC; Huang Y; Lan HY; Szeto CC; So WY; Chan JCN; Ma RCW;
Am J Kidney Dis; 2022 Aug; 80(2):196-206.e1. PubMed ID: 34999159
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of spot versus 24-hour measures of proteinuria for death, end-stage kidney disease or chronic kidney disease progression.
Ying T; Clayton P; Naresh C; Chadban S
BMC Nephrol; 2018 Mar; 19(1):55. PubMed ID: 29514605
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and correlates of gout in a large cohort of patients with chronic kidney disease: the German Chronic Kidney Disease (GCKD) study.
Jing J; Kielstein JT; Schultheiss UT; Sitter T; Titze SI; Schaeffner ES; McAdams-DeMarco M; Kronenberg F; Eckardt KU; Köttgen A;
Nephrol Dial Transplant; 2015 Apr; 30(4):613-21. PubMed ID: 25395390
[TBL] [Abstract][Full Text] [Related]
8. Comparison between urine albumin-to-creatinine ratio and urine protein dipstick testing for prevalence and ability to predict the risk for chronic kidney disease in the general population (Iwate-KENCO study): a prospective community-based cohort study.
Koeda Y; Tanaka F; Segawa T; Ohta M; Ohsawa M; Tanno K; Makita S; Ishibashi Y; Itai K; Omama SI; Onoda T; Sakata K; Ogasawara K; Okayama A; Nakamura M
BMC Nephrol; 2016 May; 17(1):46. PubMed ID: 27169575
[TBL] [Abstract][Full Text] [Related]
9. Urine Markers of Kidney Tubule Cell Injury and Kidney Function Decline in SPRINT Trial Participants with CKD.
Malhotra R; Katz R; Jotwani V; Ambrosius WT; Raphael KL; Haley W; Rastogi A; Cheung AK; Freedman BI; Punzi H; Rocco MV; Ix JH; Shlipak MG
Clin J Am Soc Nephrol; 2020 Mar; 15(3):349-358. PubMed ID: 32111704
[TBL] [Abstract][Full Text] [Related]
10. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
Jongs N; Greene T; Chertow GM; McMurray JJV; Langkilde AM; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL;
Lancet Diabetes Endocrinol; 2021 Nov; 9(11):755-766. PubMed ID: 34619106
[TBL] [Abstract][Full Text] [Related]
11. Risk of Progression of Nonalbuminuric CKD to End-Stage Kidney Disease in People With Diabetes: The CRIC (Chronic Renal Insufficiency Cohort) Study.
Koye DN; Magliano DJ; Reid CM; Jepson C; Feldman HI; Herman WH; Shaw JE
Am J Kidney Dis; 2018 Nov; 72(5):653-661. PubMed ID: 29784612
[TBL] [Abstract][Full Text] [Related]
12. Association of Serum Uromodulin with Death, Cardiovascular Events, and Kidney Failure in CKD.
Steubl D; Schneider MP; Meiselbach H; Nadal J; Schmid MC; Saritas T; Krane V; Sommerer C; Baid-Agrawal S; Voelkl J; Kotsis F; Köttgen A; Eckardt KU; Scherberich JE;
Clin J Am Soc Nephrol; 2020 May; 15(5):616-624. PubMed ID: 32291270
[TBL] [Abstract][Full Text] [Related]
13. Urine Metabolite Levels, Adverse Kidney Outcomes, and Mortality in CKD Patients: A Metabolome-wide Association Study.
Steinbrenner I; Schultheiss UT; Kotsis F; Schlosser P; Stockmann H; Mohney RP; Schmid M; Oefner PJ; Eckardt KU; Köttgen A; Sekula P;
Am J Kidney Dis; 2021 Nov; 78(5):669-677.e1. PubMed ID: 33839201
[TBL] [Abstract][Full Text] [Related]
14. Association between non-malignant monoclonal gammopathy and adverse outcomes in chronic kidney disease: A cohort study.
Fenton A; Chinnadurai R; Gullapudi L; Kampanis P; Dasgupta I; Ritchie J; Harding S; Ferro CJ; Kalra PA; Taal MW; Cockwell P
PLoS Med; 2020 Feb; 17(2):e1003050. PubMed ID: 32109242
[TBL] [Abstract][Full Text] [Related]
15. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Zelniker TA; Raz I; Mosenzon O; Dwyer JP; Heerspink HHJL; Cahn A; Goodrich EL; Im K; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson I; Langkilde AM; Sabatine MS; Wiviott SD
JAMA Cardiol; 2021 Jul; 6(7):801-810. PubMed ID: 33851953
[TBL] [Abstract][Full Text] [Related]
16. Sex Differences in the Progression of CKD Among Older Patients: Pooled Analysis of 4 Cohort Studies.
Minutolo R; Gabbai FB; Chiodini P; Provenzano M; Borrelli S; Garofalo C; Bellizzi V; Russo D; Conte G; De Nicola L;
Am J Kidney Dis; 2020 Jan; 75(1):30-38. PubMed ID: 31409508
[TBL] [Abstract][Full Text] [Related]
17. Relationship of coronary artery calcification with renal function decline and mortality in predialysis chronic kidney disease patients.
Lamarche MC; Hopman WM; Garland JS; White CA; Holden RM
Nephrol Dial Transplant; 2019 Oct; 34(10):1715-1722. PubMed ID: 30010904
[TBL] [Abstract][Full Text] [Related]
18. Progression of Chronic Kidney Disease Risk Categories and Risk of Cardiovascular Disease and Total Mortality: Coronary Artery Risk Development in Young Adults Cohort.
Choi Y; Jacobs DR; Shroff GR; Kramer H; Chang AR; Duprez DA
J Am Heart Assoc; 2022 Nov; 11(21):e026685. PubMed ID: 36314497
[TBL] [Abstract][Full Text] [Related]
19. Chronic kidney disease, cardiovascular disease and mortality: A prospective cohort study in a multi-ethnic Asian population.
Lim CC; Teo BW; Ong PG; Cheung CY; Lim SC; Chow KY; Meng CC; Lee J; Tai ES; Wong TY; Sabanayagam C
Eur J Prev Cardiol; 2015 Aug; 22(8):1018-26. PubMed ID: 24857889
[TBL] [Abstract][Full Text] [Related]
20. Plasma concentrations of osteopontin, but not thrombin-cleaved osteopontin, are associated with the presence and severity of nephropathy and coronary artery disease in patients with type 2 diabetes mellitus.
Yan X; Sano M; Lu L; Wang W; Zhang Q; Zhang R; Wang L; Chen Q; Fukuda K; Shen W
Cardiovasc Diabetol; 2010 Oct; 9():70. PubMed ID: 21034455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
